This study investigated mortality and causes of death between 1988 and 1999 in 14 781 persons (6702 female) with Down syndrome in California, comparing age, sex, ethnicity, and other factors. Mean age at the start of follow-up was 14 years 8 months (SD 14y 10mo). During the study period 600 persons died. The standardized mortality ratio (SMR) for the population was 5.5. Blacks were at greater risk than whites, Hispanics, or Asians (relative risk=1.5). Mortality declined during the period, especially for children with congenital heart defects. Leukemia (SMR=17), respiratory illnesses (SMR=27), congenital anomalies (SMR=72), and circulatory diseases (SMR=5.3) accounted for most of the excess mortality. With the exception of leukemia, cancer mortality was not different from that of the general population.
It is well documented that persons with Down syndrome (DS) have higher mortality rates than the general population (Dupont et al. 1986 , Baird and Sadovnick 1987 , Eyman et al. 1991 , Strauss and Eyman 1996 , Strauss and Zigman 1996 , Hayes et al. 1997 , Hijii et al. 1997 , Singer and Strauss 1997 , Strauss and Shavelle 1998 , Frid et al. 1999 , Hermon et al. 2001 , Yang et al. 2002 . Death rates in DS have been shown to increase sharply after age 40 years (Dupont et al. 1986 , Eyman et al. 1991 , Strauss and Eyman 1996 , Strauss and Shavelle 1998 , while motor and cognitive skills decline Zigman 1996, Day 2001) .
Survival in DS has improved over the past few decades (Dupont et al. 1986 , Baird and Sadovnick 1987 , Hayes et al. 1997 , Eyman et al. 1991 , Hermon et al. 2001 , Glasson et al. 2002 , Yang et al. 2002 ; one study has reported a life expectancy nearing 60 years (Glasson et al. 2002) .
The most common causes of death in DS include leukemia, respiratory illnesses, congenital circulatory defects, diseases of the digestive system, Alzheimer's disease, and epilepsy (Hermon et al. 2001 , Hill et al. 2003 . Some have suggested that persons with DS might be at lower risk of some cancer morbidity or mortality (Hasle et al. 2000 , Yang et al. 2002 than the general population, but other recent studies have found no significant difference for solid tumors (Hermon et al. 2001) or even a significant excess (Hill et al. 2003) .
Racial or ethnic differences in mortality in DS were studied by Yang et al. (2002) , who used death certificates to demonstrate that median age at death among blacks with DS was significantly lower than that of whites. In a population with DS in Western Australia, Leonard et al. (2000) found significantly poorer survival among Aboriginal children than among nonAboriginal children, mirroring the pattern in the general population in Australia. Bishop et al. (1997) reported significant differences in rates of DS births among different racial groups (i.e. a higher rates in Hispanics compared with whites at maternal ages under 40 years), even after controlling for prenatal diagnosis and elective abortion.
Congenital heart defects (CHD) are common in DS, with incidence estimates ranging from 25 to 48%, perhaps depending in part on the method of diagnosis (Frid et al. 1999) . Surgical repair of heart defects in children with DS has become more common over the past 20 years, resulting in improved survival in children with DS and CHD during this period (Reller and Morris 1998 , Malec et al. 1999 , Leonard et al. 2000 .
The present study focused on the following questions: (1) do mortality rates and life expectancy in DS differ by ethnic group, (2) are mortality rates for DS continuing to fall, and (3) which causes of death are elevated in DS?
Method

PARTICIPANTS
Participants were drawn from persons receiving services from the Department of Developmental Services (DDS) in California between 1 January 1988 and 31 December 1999. Persons were identified as having DS based on an ICD-9 code (World Health Organization 1977) of 758, 758.0, or 758.00 on the Client Development Evaluation Report (CDER; DDS 1986). The CDER contains psychological, medical, functional, behavioral, and cognitive items. Reliability of the functional items and some medical items has been assessed and judged satisfactory (Citygate Associates 1998). According to Eyman et al. (1991, p 605) : 'Down syndrome is usually diagnosed at birth, and chromosomal studies are usually performed shortly thereafter. Regional Center physicians are responsible for confirming, or making, the diagnosis of Down syndrome and if karyotyping has not been carried out the physicians arrange for it to be performed'.
MORTALITY INFORMATION
Mortality information was obtained from the State of California annual electronic death records (State of California 1988 -1999 . For each age group the number of observed deaths divided by the number of person-years of exposure gave the mortality rate. Person-years were stratified to make univariate comparisons of mortality rates. Logistic regression on person-years was used to make controlled comparisons. In this method, each person-year is associated with an outcome variable, such as death, and explanatory variables such as sex, age, ethnicity, or calendar year. This person-year approach has been used frequently in the Framingham heart study (Cupples et al. 1998 ) and elsewhere (Strauss et al. 1999 (Strauss et al. , 2000 .
EXPOSURE
Exposure was calculated as the time from first CDER indicating DS until the earliest of the following: (1) date of death, (2) end of the study period (31 December 1999), or (3) 3 years after the last CDER. The third criterion was included to reduce potential bias owing to the migration of persons from California. Deaths of such people would not appear in our records, but because of the third condition the exposure time during which they might have died would be brief.
STATISTICS
Comparisons of mortality rates across different ethnic or racial groups were made in pairwise fashion, controlling for age with Cochran-Mantel-Haenszel statistics. Observed deaths and exposure were sufficient to obtain reliable estimates of mortality rates for the study group up to ages 65 to 69 years. Beyond age 69 years the relative risk from the age group 65 to 69 years was used to adjust mortality rates in the US general population (mixed 60% male to 40% female to match the study population). Life tables based on resulting mortality rates at all ages were constructed by standard methods (Anderson 1999 We tested for a decline in age-specific mortality rates during the study period by stratifying the occurrence and exposure data by age and by two time periods, 1988 to 1993 and 1994 to 1999 . This was performed separately for persons with and without CHD.
Cause-specific death rates in DS were compared with those in the Californian general population by the following method. (1) For each cause of death considered, age-specific mortality rates (deaths per 100000 person-years of exposure) in the Californian general population were computed from state mortality data (State of California 1988 -1999 was determined. (3) Mortality rates from step 1 were applied to the exposure times in step 2 to determine expected numbers of deaths due to each cause for each age group. (4) The observed number of deaths due to each cause in the DS population at each age group was noted. (5) Standardized mortality ratios (SMRs) were computed for each age group as the ratio of the observed number of deaths to the expected number (Kahn and Sempos 1989) . By summing observed and expected numbers over age groups, overall SMRs for each cause were computed. (6) Confidence intervals (CIs) for the SMRs, based on the assumption that the observed number of deaths follows a Poisson distribution, were derived by using the tables given in Brackenridge and Elder (1998). By determining causes of death in the DS group using the same source of mortality information as in the general California population, the effect on resulting SMRs of various sources of potential reporting bias was minimized.
ETHICAL APPROVAL This study received ethical approval from the Institutional Review Board of the Office of Research Affairs, University of California, Riverside. Table I describes the 1988 to 1999 study population of 14 781 persons with DS. There were 600 deaths among persons with DS during the study period. Table II provides the person-years of exposure, observed numbers of deaths, and mortality rates by age group for the entire study population. Mortality rates did not differ significantly by sex, and deaths and exposure were combined across sexes for subsequent analyses. No significant difference in mortality rates among whites, Hispanics, and Asians with DS was found, and these three groups were combined for further comparisons. Although mortality rates for blacks did not differ significantly from other ethnic groups within any age stratum, overall mortality rates for blacks were higher than for the white/Hispanic/Asian group: Cochran-Mantel-Haenszel common odds ratio 1.53 (95% CI 1.04 to 2.27). For these comparative analyses, person-years were excluded for those with CHDs, leukemia, or those who had ever been tube fed. Table III is the life table for the white/Hispanic/Asian group with DS, giving a life expectancy of 53.5 additional years for 2-year-olds with DS. Exposure and numbers of observed deaths for blacks were insufficient to give reliable estimates of mortality rates in some age strata, but adjusting mortality rates for the white/Hispanic/Asian group according to the common odds ratio of 1.53 resulted in a life table for blacks (not shown) with a life expectancy of 48.7 additional years for 2-year-olds. This is 9% less than for the white/Hispanic/Asian group. By comparison, 2-year-old blacks in the US general population have a life expectancy 8% less than that of whites.
Results
Persons with DS and CHD had significantly higher mortality rates than those without CHD. Table IV shows the rates for each group, relative risks, and excess death rates.
Mortality rates were lower in the later half of the study period (1994 to 1999) than in the earlier part (1988 to 1993) . Differences were generally not significant within an age stratum, although children aged 2 to 4 years with CHD presented a notable exception (earlier to later relative risk=6.1, p<0.001). Cochran-Mantel-Haenszel statistics showed a significant secular trend overall, with common odds ratios comparing mortality rates in the later period with those in the earlier of 0.54 (95% CI 0.35 to 0.81) for persons with CHD and 0.75 (95% CI 0.63 to 0.90) for those without. Table V gives observed and age-adjusted expected numbers of deaths due to specific causes, with expected numbers based on Californian general population mortality rates for 1988 to 1999. In all, there were 600 deaths observed and 109.5 expected, giving an overall SMR of 5.5 and a total of 491 more deaths than expected. Excluding 115 deaths in which the underlying cause was 'Down syndrome', there remained 376 excess deaths. Causes of death accounting for 78% of these 376 excess deaths were leukemia (n=17, SMR=17, 95% CI 11 to 25), congenital anomalies of the circulatory system (n=75, SMR=94, 95% CI 74 to 117), respiratory diseases (n=111, SMR=27, 95% CI 22 to 32), and diseases of the circulatory system, other than congenital (n=92, SMR=-5.3, 95% CI 4.3 to 6.5).
Cancers other than leukemia accounted for 18 deaths, with 18.4 deaths expected (SMR=1, not significant). No one in the study died of lung cancer, although four deaths were expected.
Discussion
Our study finding that mortality rates did not differ by sex is consistent with previous work (Thase 1982, Strauss and Eymann 1996) , although a recent Australian study found lower rates for males (Glasson et al. 2002) .
Consistent with Yang et al. (2002) , we found higher mortality in blacks than in whites, a pattern consistent with that of the US general population. The reason for this difference in DS, as Hermon et al. (2001; n=622) Hill et al. (2003; n=742) 4 -7.8 in the general population (Guralnik et al. 1993 , Wong et al. 2002 remains unclear and warrants further investigation. Our results on causes of death largely agree with two other recent studies (Hermon et al. 2001 , Hill et al. 2003 . Table VI compares the three studies. Differences may be attributable to different age distributions, sampling variation, different methods of coding causes of death, or possible biases in identifying causes of death.
The significantly small number of observed deaths due to lung cancer (observed=0, expected=4) might be explained by the low incidence of tobacco use in the DS population, as suggested by Hasle et al. (2000) . The number of cancer deaths other than leukemia was similar to that expected in the general population, contrary to Yang et al. (2002) but consistent with others (Hermon et al. 2001 , Hill et al. 2003 .
In our population of persons with DS, the proportion with CHD was about 12%. This is lower than other studies have suggested (Frid et al. 1999) . The difference might be partly due to the fact that the CDER does not identify mild cases of CHD. According to the CDER manual (California Department of Developmental Services 1986, chapter VII, section 12, p 1) a medical condition included in a client's annual report 'indicates the presence of major, chronic medical problems that limit or impede the client or significantly impact the provision of services'. Mild CHD or a successfully repaired CHD might have little impact on a patient's well-being (Hijii et al. 1997 ) and thus might not be noted on the CDER.
It was not surprising to find that persons with CHD had higher mortality rates than those without. This difference was substantially larger in adults than in children: adults with CHD were subject to an extra mortality rate of about 10 deaths per 1000 person-years at ages 20 to 29 years, rising to more than 34 deaths per 1000 person-years at age 50 years and above. A trend over time toward more frequent repair of CHD in DS children, or recent improvements in surgical techniques, might explain this pattern. Another possible explanation is that the adverse effect of CHD might become worse with increasing age. In either case, this finding could have implications for possible surgical treatment of adults with CHD.
The decline in mortality over time has been reported by others (Dupont et al. 1986 , Baird and Sadovnick 1987 , Eyman et al. 1991 , Hayes et al. 1997 , Hermon et al. 2001 , Yang et al. 2001 . In the present study, death rates declined markedly among children 2 to 4 years of age with CHD, from 10.6 deaths per 1000 person-years in the earlier period (1988 to 1993) to 1.7 per 1000 in the later period (1994 to 1999). A smaller, but still statistically significant, decline was observed for older children. However, no significant trend was observed for adult mortality. As noted above and elsewhere, this finding might be explained in part by increasing surgical repair of CHD in children with DS, and by improvements in surgical procedures (Reller and Morris 1998 , Malec et al. 1999 , Leonard et al. 2000 . Because we do not currently have information in our database indicating whether a person's heart defect was surgically repaired, we were unable to explore this conjecture.
Mortality rates of persons with DS remain higher overall than those of the general population with many, though not all, major causes of death contributing to the difference. The findings reported here suggest many further questions and research opportunities, especially regarding the causal mechanisms of the mortality differences, including possible genetic links to aging or cancer. The findings here and in the future may have important implications for persons with and without DS. We are seeking a BC/BE Physiatrist with an interest in establishing a combined pediatric/adult practice. The ideal candidate would collaborate closely with pediatric orthopedics and pediatric neurology, and would join an existing 7-member PM&R department at the Marshfield Center.
Marshfield Clinic is a physician-directed multi-specialty group practice, with over 80+ medical specialties, a nationally known research facility, residency programs, and a highly rated health plan. The clinic adjoins a 504-bed acute care facility with an inpatient adult rehab unit.
Physicians enjoy the amenities of state of the art equipment and excellent support staff. You can expect a competitive two-year guaranteed salary and comprehensive benefit package.
With a population of nearly 20,000, Marshfield offers residents a safe, clean community with a host of recreation and entertainment opportunities. Marshfield is located in the heart of the state's winter and summer recreational areas and boasts fine primary and secondary educational facilities plus a two and four year university campus and area technical college. Wisconsin has been named one of the six "smartest states" in the country based on the quality of its public elementary and secondary schools. No long daily commute either…the outskirts of town are a mere five-minute drive from the Clinic complex. This special living environment is enhanced by a practice opportunity that can offer you professional excellence and strong economic stability.
If you are interested in providing high quality health care and would like more information on this opportunity, please contact: Mary Treichel, Physician Recruitment, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449. Telephone: 1-800-782-8581, ext. 19774; Fax #: 715-221-9779 ; E-mail: treichel.mary@marshfieldclinic.org VISIT OUR WEBSITE: www.marshfieldclinic.org/recruit Making a difference, one patient at a time.
Marshfield Clinic is an Affirmative Action/Equal Opportunity employer that values diversity. Minorities, females, individuals with disabilities and veterans are encouraged to apply. Sorry. Not a health professional shortage area.
